Author

Owen Bowles

Observed name: O. Bowles

Institution: Clovis Oncology (United States)

Observed institution: Clovis Oncology (United States)

OpenAlex ID: A5080006887

Abstract CT251: LuMIERE: A phase 1/2 study investigating safety, pharmacokinetics, dosimetry, and preliminary antitumor activity of 177Lu-FAP-2286 in patients with advanced or metastatic solid tumors

2022 · Jonathan McConathy, Mallika Dhawan, et al. · Cancer Research · 10

312 Aries: a phase 2, open-label study to evaluate rucaparib (PARP inhibitor) in combination with nivolumab (Anti-PD-1 Antibody) in patients with ovarian or urothelial cancer (UC)

2019 · K. Moore, K. Redhead, et al. · International Journal of Gynecological Cancer

Works count: 2

Citation count: 10

H-index: 1

I10-index: 1